Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash.
| Revenue (Most Recent Fiscal Year) | $1.45M |
| Net Income (Most Recent Fiscal Year) | $-79.28M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 217.08 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -7899.92% |
| Net Margin (Trailing 12 Months) | -7688.50% |
| Return on Equity (Trailing 12 Months) | -33.37% |
| Return on Assets (Trailing 12 Months) | -28.44% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.58 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.85 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 74.26M |
| Free Float | 71.50M |
| Market Capitalization | $268.09M |
| Average Volume (Last 20 Days) | 0.66M |
| Beta (Past 60 Months) | 1.17 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.72% |
| Percentage Held By Institutions (Latest 13F Reports) | 54.66% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |